{"id":5037,"date":"2020-06-03T10:00:37","date_gmt":"2020-06-03T08:00:37","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2020\/10\/07\/innovative-pulsatile-heart-pumps-for-acute-patients-novapump-secures-seven-digit-financing-round\/"},"modified":"2020-11-05T11:48:02","modified_gmt":"2020-11-05T10:48:02","slug":"innovative-pulsatile-heart-pumps-for-acute-patients-novapump-secures-seven-digit-financing-round","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2020-en\/innovative-pulsatile-heart-pumps-for-acute-patients-novapump-secures-seven-digit-financing-round\/","title":{"rendered":"Innovative Pulsatile Heart Pumps for Acute Patients: NovaPump secures seven-digit Financing Round"},"content":{"rendered":"

NovaPump, one of the leading developers and medical product manufacturers of percutaneous circulatory mechanical support systems (pMCS) announced the successful closing of a series A financing round with a consortium of institutional and strategic investors.<\/h3>\n
NovaPump\u2019s PERKAT\u2122 (PERku\u00adtane KATheter\u00adpumpe) short term MCS for acute patients achieved impor\u00adtant mile\u00adstones within the last months. With this financ\u00ading round it is pos\u00adsi\u00adble to develop the PERKAT\u2122 prod\u00aducts fur\u00adther to the first-in-man (FIM) tri\u00adals. The PERKAT RV device can be implanted to increase car\u00addiac out\u00adput (CO) of patients, who suf\u00adfer from acute heart fail\u00adure due to pul\u00admonary embolism or myocar\u00addial infarc\u00adtion. Cur\u00adrently, these patients have an extremely high mor\u00adtal\u00adity rate. The MCS improves CO if drug treat\u00adment fails to sta\u00adbi\u00adlize the hemo\u00addy\u00adnamic con\u00addi\u00adtion in such cases. The PERKAT MCS from Nova\u00adPump employs a unique self-expand\u00ading mech\u00ada\u00adnism of the pump cham\u00adber. PERKAT is com\u00adpletely catheter-based, ECG con\u00adtrolled, and com\u00adbines phys\u00adi\u00ado\u00adlogic pul\u00adsatile mech\u00ada\u00adnism and an auto\u00admated pump mode. Prof Markus Fer\u00adrari (MD), co-founder and inven\u00adtor of PERKAT explained: \u201cOur heart pumps can be implanted under X\u2011Ray con\u00adtrol within a few min\u00adutes. They work in a pul\u00adsatile man\u00adner using ECG or pres\u00adsure trig\u00adger to phys\u00adi\u00ado\u00adlog\u00adi\u00adcally sup\u00adport the fail\u00ading human heart. Post CE approval, our devices will be a mean\u00ading\u00adful appli\u00adca\u00adtion for cur\u00adrent IABP (Intra Aor\u00adtic Bal\u00adloon Coun\u00adter\u00adpul\u00adsa\u00adtion) tech\u00adnol\u00adogy, which is avail\u00adable for treat\u00adment in most heart cen\u00adtres world\u00adwide today. The PERKAT heart pumps can fur\u00adther increase our ther\u00ada\u00adpeu\u00adtic options with MCS in car\u00addio\u00adgenic shock patients.\u201d Ronald Reich, founder and CEO added: \u201cWe are very pleased about the trust placed in us from our new investors (a global med-tech com\u00adpany) and our seed investors HTGF and bm\u2011t. We will use these A\u2011round funds to fur\u00adther progress on our next mile\u00adstones, includ\u00ading the planned clin\u00adi\u00adcal trial for our right heart pump and to advance our research col\u00adlab\u00ado\u00adra\u00adtions with our R&D part\u00adners in the field of short-term mechan\u00adi\u00adcal cir\u00adcu\u00adla\u00adtion sup\u00adport.\u201d Dr Mar\u00adtin Pfis\u00adter, senior invest\u00adment man\u00adager from HTGF com\u00admented: \u201cWith this invest\u00adment round Nova\u00adPump has attained the nec\u00ades\u00adsary bud\u00adget to develop the PERKAT heart pumps fur\u00adther to the first in man trial. We are pleased to be invest\u00ading as part of a strong con\u00adsor\u00adtium with a global med-tech part\u00adner who extends the capa\u00adbil\u00adi\u00adties of Nova\u00adPump with deep indus\u00adtry exper\u00adtise in this field.\u201d In Ger\u00admany alone there are about 250.000 cases of myocar\u00addial infarc\u00adtion annu\u00adally. Over the last two decades, since hav\u00ading mod\u00adern per\u00adcu\u00adta\u00adneous MCS avail\u00adable, the mor\u00adtal\u00adity rate after an acute myocar\u00addial infarc\u00adtion could be decreased effec\u00adtively due to this novel cut\u00adting-edge tech\u00adnique. Today\u2019s per\u00adcu\u00adta\u00adneous MCS could be implanted in the catheter lab via the leg ves\u00adsels (Seldingers\u2019 tech\u00adnique) directly to the humans heart within an implan\u00adta\u00adtion time of less than 15 min\u00adutes. Self-expand\u00ading and espe\u00adcially pul\u00adsatile catheter-based MCS like the PERKAT heart pumps will offer clin\u00adi\u00adcians a fur\u00adther phys\u00adi\u00ado\u00adlog\u00adi\u00adcally opti\u00admized ther\u00adapy option and aim to save addi\u00adtional mul\u00adti\u00adple thou\u00adsands of lives annually.<\/div>\n

About NovaPump<\/a><\/strong><\/h3>\n
The Jena-based car\u00addi\u00adol\u00adogy start-up is devel\u00adop\u00ading new kinds of mechan\u00adi\u00adcal sup\u00adport sys\u00adtems (MCS) for acute patients that are per\u00adcu\u00adta\u00adneous, self-expand\u00ading, and pul\u00adsatile. These MCS are intended for tem\u00adpo\u00adrary use with a max\u00adi\u00admum dura\u00adtion of 14 days. The company\u00b4s orig\u00adi\u00adnal PERKAT RV right-heart pump was largely grant funded by the BMBF (Fed\u00aderal Min\u00adistry of Edu\u00adca\u00adtion and Research), and the BMBF is also now fund\u00ading the devel\u00adop\u00adment of a next gen\u00ader\u00ada\u00adtion left heart pump through a research net\u00adwork con\u00adsor\u00adtium. Nova\u00adPump was founded by a team of sci\u00aden\u00adtists, clin\u00adi\u00adcians and busi\u00adness econ\u00ado\u00admists in Jena, Ger\u00admany in 2012.<\/div>\n

About bm|t<\/a><\/strong><\/h3>\n
Erfurt-based, bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment Th\u00fcrin\u00adgen (bm|t) \u2013 a sub\u00adsidiary of the Th\u00fcrin\u00adgen Devel\u00adop\u00adment Bank, is the first address for invest\u00adments in Th\u00fcrin\u00adgen, Ger\u00admany. bm\u2011t cur\u00adrently man\u00adages eight invest\u00adment funds with a total vol\u00adume of 400M EUR. bm\u2011t invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies with strong growth poten\u00adtial across all sec\u00adtors and all phases of the cor\u00adpo\u00adrate lifecycle.<\/div>\n

About Sparkasse Jena<\/a><\/strong><\/h3>\n
The Sparkasse Jena-Saale-Hol\u00adz\u00adland is the largest regional finan\u00adcial part\u00adner and has been rooted in the region since 1828. Invest\u00adments such as those in Nova\u00adPump are an impor\u00adtant con\u00adtri\u00adbu\u00adtion to eco\u00adnomic devel\u00adop\u00adment in the region. This is why Sparkasse Jena-Saale-Hol\u00adz\u00adland will con\u00adtinue to sup\u00adport fur\u00adther busi\u00adness start-ups in the future. The strong regional know-how is thus bun\u00addled through good net\u00adwork\u00ading and is intended to sup\u00adport the dynamic start-up scene.<\/div>\n

About High-Tech Gr\u00fcnderfonds<\/a><\/strong><\/h3>\n
The seed investor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) finances tech\u00adnol\u00adogy start-ups with growth poten\u00adtial. With a vol\u00adume of approx\u00adi\u00admately 900 mil\u00adlion euros dis\u00adtrib\u00aduted over three funds and an inter\u00adna\u00adtional part\u00adner net\u00adwork, the HTGF has sup\u00adported almost 600 start-ups since 2005. Its team of expe\u00adri\u00adenced invest\u00adment man\u00adagers and start-up experts sup\u00adport the young com\u00adpa\u00adnies with know-how, entre\u00adpre\u00adneur\u00adial spirit and pas\u00adsion. The focus lies on high-tech start-ups in the fields of dig\u00adi\u00adtal busi\u00adness mod\u00adels, indus\u00adtrial tech\u00adnol\u00adogy, life sci\u00adences, chem\u00adistry and related busi\u00adness areas. To date, exter\u00adnal investors have invested more than 2.4 bil\u00adlion euros of cap\u00adi\u00adtal in the HTGF port\u00adfo\u00adlio in more than 1,500 fol\u00adlow-up financ\u00ading rounds. The fund has also suc\u00adcess\u00adfully sold shares in more than 100 com\u00adpa\u00adnies. Con\u00adtact<\/strong> Nova\u00adPump GmbH Ronald Reich, Am Stein\u00adborn 103a 07749 Jena T.: +49 3641 4814938 info@novapump.de<\/span><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Nova\u00adPump, one of the lead\u00ading devel\u00adop\u00aders and med\u00adical prod\u00aduct man\u00adu\u00adfac\u00adtur\u00aders of per\u00adcu\u00adta\u00adneous cir\u00adcu\u00adla\u00adtory mechan\u00adi\u00adcal sup\u00adport sys\u00adtems (pMCS) announced the suc\u00adcess\u00adful clos\u00ading of a series A financ\u00ading round with a con\u00adsor\u00adtium of insti\u00adtu\u00adtional and strate\u00adgic investors. NovaPump\u2019s PERKAT\u2122 (PERku\u00adtane KATheter\u00adpumpe) short term MCS for acute patients achieved impor\u00adtant mile\u00adstones within the last months. With this financing [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":8913,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[149],"tags":[177,159,202,171,175,174],"class_list":["post-5037","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2020-en","tag-bmt-en","tag-investment-en","tag-press","tag-thuringia","tag-thuringia-growth-fund","tag-wbf-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/5037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=5037"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/5037\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/8913"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=5037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=5037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=5037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}